HENRY HE

Fangda Partners

+86 21 2208 1185
henry.he@fangdalaw.com

PRACTICE AREAS

MR. HE SPECIALIZES IN COMPLEX LIFE SCIENCES TRANSACTIONS INCLUDING LICENSING, STRATEGIC PARTNERING, FINANCING AND CORPORATE M&A.

REPRESENTATIVE MATTERS AND CASES

- Advised on the multi-faceted strategic collaboration with Pfizer Corp. including a US$200 million share sale, on (i) PD-L1 monoclonal antibody (CS1001)'s China commercialization and (ii) subsequent co-development of Pfizer pipeline assets (including Lorlatinib) and potential joint in-license.
- Advised on out-licensing of PD-L1 mAb (CS1001) and PD-1 mAb (CS1003)'s development and commercialization rights in ex-China region to EQRx Inc.
- Advised on the exclusive collaboration and license agreement with LegoChem Biosciences Inc. to develop, manufacture and commercialize LCB71 (ROR1 ADC) for entire world excluding Korea.
- Advised on the out-licensing of CTLA-4 mAb (CS1002)'s development and commercialization rights in Greater China to Jiangsu Hengrui Pharmaceuticals.
- Advised on the exclusive collaboration and license agreement with Blueprint Medicines Corporation to develop, manufacture and commercialize Avapritinib (KIT/PDGFRA inhibitor), Fisogatinib (FGFR4 inhibitor) and Pralsetinib (RET inhibitor) in mainland China, Hong Kong, Macau and Taiwan.
- Advised on the exclusive collaboration and license agreement with Agios Pharmaceuticals, Inc. to develop, manufacture and commercialize Ivosedinib (IDH1 inhibitor) in mainland China, Hong Kong, Macau and Taiwan.

- Advised on the exclusive collaboration and license agreement with WuXi Biologics to develop, manufacture and commercialize a tri-functional molecule and an antibody-drug conjugate (ADC) in the entire world.
- Advised on the Research Collaboration, Option and License Agreement with DotBio Pte. Ltd. for exclusive global rights of up to three multi-specific antibody and/or ADC development candidates.
- Advised on the global collaboration agreement with Bayer Healthcare LLC for evaluating the combination of CStone Pharmaceutical's PD-L1 drug, Sugemalimab, with Bayer's regorafenib, an oral multi-kinase inhibitor (targeting VEGFR, FGFR, CSF1R, etc.), for use in the treatment of multiple cancers including gastric cancer.
- Advised on the discovery collaboration with Numab Therapeutics to fund the research development and obtain the rights to develop, manufacture and commercialize the PD-L1/4-1BB/HAS tri-specific antibody in mainland China, Hong Kong, Macau, Taiwan, Singapore and Korea.

OTHER INFORMATION

Education

- East China University of Political Science and Law, LL.B., 2010
- University of Wisconsin Madison, LL.M., 2012
- East China University of Political Science and Law, LL.M., 2013

Professional Qualification

- Admitted to practice in Massachusetts
- Admitted to practice in PRC

Work Language

- Mandarin
- English

Professional Background

Mr. He joined Fangda as a partner in 2023. Prior to joining the firm, Mr. He worked as the Board Secretary, Associate Vice President and General Counsel at a well-renowned public biopharmaceutical company. Before moving in-house, Mr. He had worked at two reputable international law firms for many years, representing venture capital funds, emerging companies and multinational corporations with exposure to early-stage financing and pre-IPO restructuring, licensing, venture capital, offshore/onshore ESOP matters and corporate M&A.